Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Piper Sandler began coverage on Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target on the stock. Clear Str raised shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Finally, B. Riley Financial initiated coverage on shares of Palisade Bio in a report on Friday, January 9th. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

Palisade Bio Trading Up 9.3%

NASDAQ PALI opened at $1.64 on Friday. The company has a market cap of $244.36 million, a PE ratio of -0.77 and a beta of 1.58. Palisade Bio has a 12 month low of $0.53 and a 12 month high of $2.64. The stock has a 50 day moving average of $1.90 and a 200-day moving average of $1.51.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Monday, November 10th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). As a group, sell-side analysts predict that Palisade Bio will post -12.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Palisade Bio

An institutional investor recently bought a new position in Palisade Bio stock. Total Clarity Wealth Management Inc. acquired a new position in Palisade Bio, Inc. (NASDAQ:PALI) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 29,935 shares of the company’s stock, valued at approximately $70,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.